A combination of sorafenib and radiotherapy reduces NF-κB activity and growth of hepatocellular carcinoma in an orthotopic mouse model

Hepatocellular carcinoma (HCC) is difficult to diagnose at an early stage, and its prognosis is generally poor. Sorafenib is the primary treatment for unresectable advanced HCC and targets multiple receptor tyrosine kinases. However, sorafenib only extends the average survival time by 3 months. This...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncol Lett
Hlavní autoři: Chuang, Hui-Yen, Tyan, Yeu-Sheng, Hwang, Jeng-Jong, Shih, Kuang-Chung, Lin, Wei-Chan
Médium: Artigo
Jazyk:Inglês
Vydáno: D.A. Spandidos 2021
Témata:
Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7933744/
https://ncbi.nlm.nih.gov/pubmed/33692869
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2021.12598
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky